NRG HN014

Official Title

Randomized Phase III Trial of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma

Study Purpose

To test if giving immunotherapy before and after (in some cases) surgery extend the length of time without your cancer returning compared to the usual approach

Diagnosis

Eligibility

Previously untreated or recurrent Stage III or IV resectable disease

Intervention

Arm 1:  Standard of care surgery + radiation vs. Arm 2:  Cemiplimab, followed by surgery + radiation, then cemiplimab